306 related articles for article (PubMed ID: 36826704)
1. Integrating Functional Imaging and Molecular Profiling for Optimal Treatment Selection in Neuroendocrine Neoplasms (NEN).
Kong G; Boehm E; Prall O; Murray WK; Tothill RW; Michael M
Curr Oncol Rep; 2023 May; 25(5):465-478. PubMed ID: 36826704
[TBL] [Abstract][Full Text] [Related]
2. Precision medicine in gastroenteropancreatic neuroendocrine neoplasms: Where are we in 2023?
Fazio N; La Salvia A
Best Pract Res Clin Endocrinol Metab; 2023 Sep; 37(5):101794. PubMed ID: 37414651
[TBL] [Abstract][Full Text] [Related]
3. [Gastroenteropancreatic neuroendocrine neoplasms-Heterogeneity, management and perspectives of treatment and research].
Luley K; Gebauer J; Gebauer N; Tharun L; Buchmann I; Barkhausen J; von Bubnoff N; Lindner K; Keck T; Lehnert H; Schmid SM
Internist (Berl); 2020 Aug; 61(8):875-890. PubMed ID: 32676723
[TBL] [Abstract][Full Text] [Related]
4. Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?
Rinke A; Auernhammer CJ; Bodei L; Kidd M; Krug S; Lawlor R; Marinoni I; Perren A; Scarpa A; Sorbye H; Pavel ME; Weber MM; Modlin I; Gress TM
Gut; 2021 Sep; 70(9):1768-1781. PubMed ID: 33692095
[TBL] [Abstract][Full Text] [Related]
5. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.
Carlsen EA; Fazio N; Granberg D; Grozinsky-Glasberg S; Ahmadzadehfar H; Grana CM; Zandee WT; Cwikla J; Walter MA; Oturai PS; Rinke A; Weaver A; Frilling A; Gritti S; Arveschoug AK; Meirovitz A; Knigge U; Sorbye H
Endocr Relat Cancer; 2019 Feb; 26(2):227-239. PubMed ID: 30540557
[TBL] [Abstract][Full Text] [Related]
6. Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.
Crown A; Rocha FG; Raghu P; Lin B; Funk G; Alseidi A; Hubka M; Rosales J; Lee M; Kennecke H
J Surg Oncol; 2020 Mar; 121(3):480-485. PubMed ID: 31853990
[TBL] [Abstract][Full Text] [Related]
7. [Gastroenteropancreatic neuroendocrine tumors].
Rayes N; Denecke T
Radiologe; 2021 Dec; 61(12):1129-1138. PubMed ID: 34727206
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.
Deppen SA; Liu E; Blume JD; Clanton J; Shi C; Jones-Jackson LB; Lakhani V; Baum RP; Berlin J; Smith GT; Graham M; Sandler MP; Delbeke D; Walker RC
J Nucl Med; 2016 May; 57(5):708-14. PubMed ID: 26769865
[TBL] [Abstract][Full Text] [Related]
9. Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy.
Viol F; Sipos B; Fahl M; Clauditz TS; Amin T; Kriegs M; Nieser M; Izbicki JR; Huber S; Lohse AW; Schrader J
Cell Oncol (Dordr); 2022 Dec; 45(6):1401-1419. PubMed ID: 36269546
[TBL] [Abstract][Full Text] [Related]
10. Identification of sequence polymorphisms in the displacement loop region of mitochondrial DNA as a risk factor for gastroenteropancreatic neuroendocrine neoplasm.
Er LM; Wu ML; Gao Y; Wang SJ; Li Y
J Clin Lab Anal; 2017 Sep; 31(5):. PubMed ID: 27704598
[TBL] [Abstract][Full Text] [Related]
11. Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions.
Deroose CM; Hindié E; Kebebew E; Goichot B; Pacak K; Taïeb D; Imperiale A
J Nucl Med; 2016 Dec; 57(12):1949-1956. PubMed ID: 27811124
[TBL] [Abstract][Full Text] [Related]
12. Endoscopic imaging in the management of gastroenteropancreatic neuroendocrine tumors.
Pellicano R; Fagoonee S; Altruda F; Bruno M; Saracco GM; De Angelis C
Minerva Endocrinol; 2016 Dec; 41(4):490-8. PubMed ID: 27600643
[TBL] [Abstract][Full Text] [Related]
13. Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models.
Kawasaki K; Fujii M; Sato T
Dis Model Mech; 2018 Feb; 11(2):. PubMed ID: 29590641
[TBL] [Abstract][Full Text] [Related]
14. The Correlation Between [
Yu J; Li N; Li J; Lu M; Leal JP; Tan H; Su H; Fan Y; Zhang Y; Zhao W; Zhu H; Pomper MG; Zhou Y; Yang Z
Mol Imaging Biol; 2019 Oct; 21(5):984-990. PubMed ID: 30796708
[TBL] [Abstract][Full Text] [Related]
15. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging.
Baumann T; Rottenburger C; Nicolas G; Wild D
Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):45-57. PubMed ID: 26971843
[TBL] [Abstract][Full Text] [Related]
16. Gastroenteropancreatic grade 3 neuroendocrine tumors: a single entity or a heterogeneous group? A retrospective analysis.
Laffi A; Spada F; Bagnardi V; Frassoni S; Pisa E; Rubino M; Barberis M; Fazio N
J Endocrinol Invest; 2022 Feb; 45(2):317-325. PubMed ID: 34282554
[TBL] [Abstract][Full Text] [Related]
17. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas.
Garcia-Carbonero R; Sorbye H; Baudin E; Raymond E; Wiedenmann B; Niederle B; Sedlackova E; Toumpanakis C; Anlauf M; Cwikla JB; Caplin M; O'Toole D; Perren A;
Neuroendocrinology; 2016; 103(2):186-94. PubMed ID: 26731334
[No Abstract] [Full Text] [Related]
18. An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms.
Fang JM; Li J; Shi J
World J Gastroenterol; 2022 Mar; 28(10):1009-1023. PubMed ID: 35431496
[TBL] [Abstract][Full Text] [Related]
19. PET-Based Molecular Imaging in Designing Personalized Management Strategy in Gastroenteropancreatic Neuroendocrine Tumors.
Basu S; Ranade R; Ostwal V; Shrikhande SV
PET Clin; 2016 Jul; 11(3):233-41. PubMed ID: 27321028
[TBL] [Abstract][Full Text] [Related]
20. Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development.
Garcia-Carbonero R; Garcia-Figueiras R; Carmona-Bayonas A; Sevilla I; Teule A; Quindos M; Grande E; Capdevila J; Aller J; Arbizu J; Jimenez-Fonseca P;
Cancer Metastasis Rev; 2015 Dec; 34(4):823-42. PubMed ID: 26433592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
